Potential Use for New GABA-Targeting Drugs in Alcohol Use Disorder

Use of GABAB (GABA type B) agonist, ADX71441, in preclinical trials caused significant reductions in alcohol intake. The drug potently reduced motivation to drink and alcohol-seeking behaviours.

Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter1. GABA is one of the neurotransmitters which has its signalling influenced by alcohol2 and it is important to the manifestation of alcohol’s physiological effects. A recent exploration into a novel GABAB (GABA type B) receptor positive allosteric modulator (a molecule which binds to an area on a receptor outside of the active site to increase the ability of molecules to bind to the receptor therefore increasing activation of the receptor) shows promising advantages in treating alcohol use disorder1.

The GABA type A (GABAA) receptor is also involved in the effects of alcohol on the central nervous system (CNS) as ethanol increases the action of GABA at GABAA receptors3. This is supported by the finding that the benzodiazepine, flumazenil, which is a negative allosteric modulator of the GABAA receptor (a molecule which binds to an area on a receptor outside of the active site to decrease the ability of molecules to bind to the receptor therefore decreasing activation of the receptor), reverses the intoxicating effects of ethanol3. Furthermore, flumazenil also removes the increase in aggression and sleepiness experienced from alcohol3 showing that the GABAA receptor is also heavily involved in alcohol’s physiological effects and is an effective target at blocking ethanol-induced behavioural changes.

The role of the GABAB receptor in alcohol use has also been explored, and a GABAB receptor agonist baclofen has been approved as treatment for alcohol use disorder in France1. GABAB receptor agonists cause anticonvulsant and anxiolytic effects, and baclofen is used to treat spasticity1. Baclofen reduces the motivation of rodents to self-administer addictive drugs, likely due to its observed effect of reducing morphine, cocaine and nicotine-induced dopamine release in the nucleus accumbens1 where dopamine release causes reinforcement of addictive behaviours4. However, despite the GABAB agonist baclofen’s ability to help treat alcohol use disorder1, baclofen has various side effects such as sedation and tolerance-development suggesting that GABAB receptor positive allosteric modulators (PAMs) may merit trials to seek a drug with a better therapeutic index1.

A novel GABAB PAM, ADX71441, in rodent trials caused significant reductions in alcohol intake (up to 65% with the highest dose of 200mg/kg)1. The drug potently reduced motivation to drink and alcohol-seeking behaviours1, suggesting inhibition of alcohol-induced dopamine response and therefore reduced addiction. ADX71441 also caused a significant reduction in alcohol-seeking caused by alcohol-predictive environments and exposure to a stress, suggesting therapeutic use in preventing alcohol use disorder relapse as more than 50% of patients relapse in only 3 months1. Preclinical studies suggest the superiority of GABAB PAMs in terms of efficacy to side effects. This warrants further research and testing to bring forth new drugs to treat alcohol use disorder1 , thereby reducing the alcohol abuse that causes a huge burden on the health and economic well being all over the world.

***

References:  

  1. Eric Augier, Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder, Alcohol and Alcoholism, Volume 56, Issue 2, March 2021, Pages 139–148, https://doi.org/10.1093/alcalc/agab003 
  1. Banerjee N. (2014). Neurotransmitters in alcoholism: A review of neurobiological and genetic studies. Indian journal of human genetics20(1), 20–31. https://doi.org/10.4103/0971-6866.132750 
  1. Davies M. (2003). The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. Journal of psychiatry & neuroscience : JPN28(4), 263–274. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165791/  
  1. Science Direct 2021. Nucleus Accumbens. Available on https://www.sciencedirect.com/topics/neuroscience/nucleus-accumbens  

*** 

Don't miss

Intermittent Fasting Can Make Us Healthier

Study shows that intermittent fasting for certain intervals can...

Longevity: Physical Activity in Middle and Older Age is Crucial

Study shows that engaging in long-term physical activity can...

Alzheimer’s Disease: Coconut Oil Decreases Plaques in Brain Cells

Experiments on mice cells shows a new mechanism pointing...

Anxiety: Matcha Tea Powder and Extract Show Promise

Scientists have demonstrated for the first time effects of...

Imperative for Nutritional Labelling

Study shows on the basis of Nutri-Score developed by...

Stay in touch:

92,144FansLike
45,781FollowersFollow
1,772FollowersFollow
51SubscribersSubscribe

Newsletter

Latest

MVA-BN Vaccinee (or Imvanex): The First Mpox Vaccine to be prequalified by WHOĀ 

The mpox vaccine MVA-BN Vaccine (i.e., Modified Vaccinia Ankara...

ā€œHearing Aid Featureā€ (HAF): The First OTC Hearing Aid Software receives FDA AuthorisationĀ 

ā€œHearing Aid Featureā€ (HAF), the first OTC hearing aid...

Mobile Phone Use Not Linked to Brain CancerĀ 

The radiofrequency (RF) exposure from mobile phones was not associated...

Type 2 Diabetes: Automated Insulin Dosing Device approved by FDA

FDA has approved the first device for automated insulin...

Does Regular Use of Multivitamins (MV) by Healthy Individuals Improve Health? Ā 

A large-scale study with lengthy follow ups has found...

Airborne Transmission redefinedĀ by WHO Ā 

Spread of pathogens through the air has been described variously by different stakeholders for long. During the COVID-19 pandemic, the terms ā€˜airborne’, ā€˜airborne transmission’...

MVA-BN Vaccinee (or Imvanex): The First Mpox Vaccine to be prequalified by WHOĀ 

The mpox vaccine MVA-BN Vaccine (i.e., Modified Vaccinia Ankara vaccine manufactured by Bavarian Nordic A/S) has become the first Mpox vaccine to be added...

Decline in Sense of Smell May be Early Sign of Health Deterioration Among Elderly

A long follow up cohort study shows that loss of sense of smell could be an early predictor of health problems and higher mortality...